65,437 trials
Polycythemia Vera (PV)
Primary: Proportion of Subjects Who Achieved Durable Phlebotomy-free Complete Hematological Response (CHR) at Month 12 — 8 Participants
Migraine
Primary: Rate of Device Related Adverse Events — 0 Participants
Pancreatic Cancer
Primary: Maximum Tolerated Dose — 50 Gray
Attention Deficit Hyperactivity Disorder
Primary: ADHD-Rating Scale (ADHD-RS) at 8 Weeks — 29.0; 23.9 units on a scale
Leukemia, Myeloid, Acute
Primary: Number of Participants With Dose-limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Flotetuzumab in Patients With Relapsed/Refractory AML Following…
Stroke
Primary: Sleep Condition Indicator Score at Post-intervention, Adjusted for Baseline Score and Sex — 18.06; 14.72 score on a scale — p=<0.021
Vaping Behaviors
Primary: Mean Vaping Quit Intentions Score — 2.5; 2.5; 2.2 score on a scale — p=<.001
Moderate to Severe Chronic Plaque Psoriasis
Primary: Psoriasis Area and Severity Index (PASI) — -79.87; -80.55 Percentage change from baseline
Intraductal Carcinoma and Lobular Carcinoma in Situ
Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants
Uremic Pruritus
Primary: Change From Baseline in the Weekly Mean of the Daily 24-hour WI-NRS Score at Week 4 of the DB Period — -2.09; -1.27 score on a scale — p=0.0003
Pain, Postoperative · Depression, Postpartum
Primary: Maximum Tolerated Dose of Ketamine — 3; 3; 3; 3 Participants
Macula; Degeneration · Retina
Primary: Change in Best Corrected Visual Acuity by ETDRS Visual Scale Testing — 2.7 Change in letters (BCVA)
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Overall Survival (OS) — 9.82; 9.23; 5.24 months — p=0.523
Healthy
Primary: Area Under the Concentration-time Curve of BI 706321 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 60.99; 133.45 Hours * nanomoles / liter
COVID-19
Primary: Number of Participants With 30-day Booster Vaccine Uptake — 14; 10 Participants